Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Freise

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|August 12, 2017
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphomaApurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, et al.
Clinical Pharmacology and Therapeutics|April 19, 2017
Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma PatientsK J Freise, A K Jones, M E Verdugo, et al.
Journal of Veterinary Pharmacology and Therapeutics|June 27, 2012
Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory BeaglesK J Freise, M C Savides, K L Riggs, et al.
Journal of Clinical Pharmacology|April 1, 2016
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 InhibitorAhmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Deutsche Medizinische Wochenschrift (1946)|January 27, 1989
[Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]B Bokemeyer, R Grote, E Schmoll, et al.
Journal of Veterinary Pharmacology and Therapeutics|July 5, 2022
Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to catsTerrence P Clark, Deborah D Linton, Kevin J Freise, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Annals of the Rheumatic Diseases|January 13, 2001
Optimised sample DNA preparation for detection of Chlamydia trachomatis in synovial tissue by polymerase chain reaction and ligase chain reactionJ Freise, H C Gérard, T Bunke, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|August 12, 2017
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphomaApurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, et al.
Clinical Pharmacology and Therapeutics|April 19, 2017
Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma PatientsK J Freise, A K Jones, M E Verdugo, et al.
Journal of Veterinary Pharmacology and Therapeutics|June 27, 2012
Pharmacokinetics and dose selection of a novel, long-acting transdermal fentanyl solution in healthy laboratory BeaglesK J Freise, M C Savides, K L Riggs, et al.
Journal of Clinical Pharmacology|April 1, 2016
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 InhibitorAhmed Hamed Salem, Suresh K Agarwal, Martin Dunbar, et al.
The AAPS Journal|May 29, 2016
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic AnalysisAksana K Jones, Kevin J Freise, Suresh K Agarwal, et al.
Deutsche Medizinische Wochenschrift (1946)|January 27, 1989
[Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]B Bokemeyer, R Grote, E Schmoll, et al.
Journal of Veterinary Pharmacology and Therapeutics|July 5, 2022
Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to catsTerrence P Clark, Deborah D Linton, Kevin J Freise, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2016
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysisKevin J Freise, Martin Dunbar, Aksana K Jones, et al.
Hematological Oncology|December 17, 2016
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergyKevin J Freise, Aksana K Jones, Rajeev M Menon, et al.
Annals of the Rheumatic Diseases|January 13, 2001
Optimised sample DNA preparation for detection of Chlamydia trachomatis in synovial tissue by polymerase chain reaction and ligase chain reactionJ Freise, H C Gérard, T Bunke, et al.
Pageof 13